Crestor Impact Review To Precede Mass. Medicaid Preferred Statin Decision
Executive Summary
Massachusetts Medicaid will assess the market impact of AstraZeneca's Crestor (rosuvastatin) before selecting a preferred statin for the program
You may also be interested in...
AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen
Public Citizen is citing AstraZeneca's marketing efforts for Crestor as one reason FDA should rapidly withdraw the statin
AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen
Public Citizen is citing AstraZeneca's marketing efforts for Crestor as one reason FDA should rapidly withdraw the statin
Mass. Medicaid Holds Line Against GSK Line Extensions
Prior authorization will be required by Massachusetts' Medicaid program for two GlaxoSmithKline antidepressant line extensions